Jennifer Waldron, DO
Neurology with Special Qualifications in Child Neurology · Cleveland, OHNPI 1902198104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $154, 3.3 times the $46 reported in 2019. That places this record below the midpoint for neurology with special qualifications in child neurology clinicians in OH, where the typical reported total is $476.
Across 18 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$75
- Biocodex, Inc.$69
- Eisai Inc.$53
- SK Life Science, Inc.$38
- Upsher-smith Laboratories LLC$35
- Otter Pharmaceuticals, LLC$29
- plus $65 from 4 others
Across 46 payments — averaging $2044.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$76K
- Biohaven Pharmaceutical Holding Company Ltd.$18K
What the payments were for
- Food & beverage$34795%
- Education$175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 4 | $75 |
| Biocodex, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $53 |
| SK Life Science, Inc. | 2 | $38 |
| Upsher-smith Laboratories LLC | 1 | $35 |
| Otter Pharmaceuticals, LLC | 1 | $29 |
| Novartis | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $13 |
How this compares
$364 in reported general payments places this provider in the 45th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.
See all neurology with special qualifications in child neurology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 11 | $245 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Cleveland
- Ajay GuptaCleveland$261K
- Aaron AbramsCleveland$88K
- Elia Pestana KnightCleveland$25K
- Jun ParkCleveland$17K
- Deepak LachhwaniCleveland$4K
- Sumit ParikhCleveland$3K
- Hope O'BrienCincinnati$525K
- Anne ConnollyColumbus$154K
- Tracy GlauserCincinnati$130K
- Cuixia TianCincinnati$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.